Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Obesity (Silver Spring, Md.) · 2021
    BTBeverly TchangFAFelicia Ann Mendelsohn CuranajJSJane SeleyMMMonika M Safford+2 more →APAlpana P. Shukla
    PMID: 33694267PMCID: PMC8206993DOISenior author24 citations
  2. 2
    The Journal of clinical endocrinology and metabolism · 2023
    BTBeverly TchangLJLouis J AronneAPAlpana P. Shukla
    PMID: 36810608PMCID: PMC10438886DOISenior author23 citations
  3. 3
    Nutrients · 2023
    APAlpana P. ShuklaLJLouis J Aronne
    PMID: 37892527PMCID: PMC10610476DOIFirst author6 citations

Publications

89 publications

Funding

3 grants

Active

2 grants
  • Sub-PI
    Association of genetic variation near the dopamine D2 receptor gene and other polymorphisms that modulate dopaminergic and opioid signaling on the weight loss response to naltrexone/bupropion
    National Institute of Diabetes and Digestive and Kidney Diseases · 2023–2027 · via Columbia University
    R01DK132527-03
  • MPI
    Nutrition for Precision Health Research Coordinating Center
    Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2022–2026 · via Cornell University - Ithaca
    U24HD107676-04
Completed grants (1)
  • Sub-PI
    Intellihealth & Novo Collaboration with Dr. Shukla (SRA)
    Novo Nordisk Pharmaceuticals, Inc. · 2022–2024 · via Intellihealth, Inc.Contract
    SRA 228477-01

Clinical research

10 studies

Active

4 studies
  • PI
    Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)
    PHASE3 · Novo Nordisk Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2026)
    Overweight; Obesity
    NCT07720271
  • PI
    A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)
    PHASE3 · Pfizer, Inc. · OPEN TO ACCRUAL (as of 2026)
    Obesity; Overweight and/or Obesity; Overweight
    NCT07595549
  • PI
    A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
    PHASE3 · Eli Lilly and Company · OPEN TO ACCRUAL (as of 2026)
    Obesity; Overweight
    NCT07357415
  • PI
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
    PHASE3 · Viking Therapeutics Inc. · OPEN TO ACCRUAL (as of 2025)
    Weight Loss
    NCT07104500
Completed & closed trials (6)
  • PI
    A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
    PHASE3 · Eli Lilly and Company · IRB STUDY CLOSURE (as of 2026)
    Obesity; Overweight
    NCT06584916
  • PI
    A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities
    PHASE3 · Eli Lilly and Company · IRB STUDY CLOSURE (as of 2025)
    Obesity; Overweight
    NCT05822830
  • PI
    Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity
    PHASE3 · Novo Nordisk Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2024)
    Obesity
    NCT06131437
  • PI
    A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
    PHASE3 · Eli Lilly and Company · CLOSED TO ACCRUAL (as of 2024)
    Obesity; Overweight; Overweight or Obesity
    NCT05869903
  • PI
    The Impact of Food Order/Nutrient Sequence on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose Monitoring
    NA · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
    Type 2 Diabetes
    NCT04738799
  • PI
    Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes
    PHASE3 · Novo Nordisk Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2023)
    Overweight; Obesity; Type 2 Diabetes Mellitus
    NCT05394519

News mentions

1 mentionView all WCM news ↗

Media highlights

1 clip

Mentoring

7 menteesAll publications with mentees →

External relationships

Advisory/Scientific Board Member

Eli Lilly and Company

Other

Novo Nordisk Pharmaceuticals, Inc. · Sun Pharmaceuticals Global FZE